HedgePath Pharmaceuticals, Inc. Announces Board Changes
April 15, 2019 at 07:41 pm IST
Share
HedgePath Pharmaceuticals, Inc. announced that the company Board of Directors has elected W. Mark Watson, CPA as Chairman of the Board, effective April 15, 2019. As previously announced, E. Brendan Magrab, HedgePath's Chairman of the Board since December 2016, is stepping down from that position in order to fulfill his duties as Chief Executive Officer of Epalex Corporation. Mr. Magrab is expected to continue to serve on the HedgePath board until the earlier of July 1, 2019 or when a new board member is identified.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.